RecruitingPhase 2NCT07522099
Chinese Adults With Kidney Disease
Studying C3 glomerulopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ADARx Pharmaceuticals, Inc.
- Principal Investigator
- Donald Fong, MD, M.DADARx Pharmaceuticals
- Intervention
- ADX-038(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (10)
- ADARx Clinical Site, Shenzhen, Guangdong, China
- ADARx Clinical Site, Guiyang, Guizhou, China
- ADARx Clinical Site, Zhengzhou, Henan, China
- ADARx Clinical Site, Baotou, Inner Mongolia, China
- ADARx Clinical Site, Wuxi, Jiangsu, China
- ADARx Clinical Site, Yantai, Shandong, China
- ADARx Clinical Site, Beijing, China
- ADARx Clinical Site, Shandong, China
- ADARx Clinical Site, Shanghai, China
- ADARx Clinical Site, Shangxi, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07522099 on ClinicalTrials.govOther trials for C3 glomerulopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07156149Fabhalta Capsules Specified Drug-use SurveyNovartis Pharmaceuticals
- RECRUITINGPHASE1NCT07483827A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathyeleva GmbH
- RECRUITINGNCT07029542Home Reported Outcomes in C3G StudyNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT04817618Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Novartis Pharmaceuticals